A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure

Official Title

A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure

Brief Summary

      AUGMENT-HF II is a study to evaluate the efficacy and safety of the Algisyl device. The
      purpose of this study is to investigate Algisyl employed as a method of left ventricular
      augmentation and restoration in patients with dilated cardiomyopathy.

      Algisyl will be injected into the myocardium under direct visualization during the surgical
      procedure. Structural abnormalities in the heart are known to play a central role in HF, and
      clinical evidence supports a strong causal relationship between cardiac chamber dilation and
      heart failure. Because dilation, and not contractile dysfunction, appears to be responsible
      for the severity of the disease, the mitigation or prevention of the deleterious structural
      abnormalities of the left ventricle appears to be an important therapeutic target for
      patients with this life threatening illness.

      Hence, a therapy that specifically reduces LV wall stress, targets LV dilatation and LV
      remodeling may offer an important new alternative in the treatment of heart failure. Algisyl
      is being investigated based on evidence that suggests an ability of the implants to reduce
      wall stress, reshape the LV chamber and reduce the LV chamber size as well as prevent the
      progressive ventricular dilation and remodeling associated with HF.

      The physiologic response to progressive exercise using direct measures of ventilation and gas
      exchange via the cardiopulmonary exercise test is an important diagnostic tool in the
      management of the patient with HF, quantifying responses to therapy, and as a reliable
      prognostic utility for predicting outcomes in patients with HF.

      Numerous studies have established the strong association of peak VO2 with mortality and
      morbidity risk in HF. Peak VO2 conceptually is considered an overall global marker of
      cardiopulmonary health and is a reflection of the degree of impairment in ventricular
      function ( the heart's pumping capacity), oxygen delivery and oxygen utilization.

      Hence, employing the change in peak VO2 as a primary endpoint in this clinical study provides
      a strong objective measure that can be interpreted in independent blinded fashion, to
      evaluate the result of the therapeutic intervention and provide an equally strong assessment
      of the prognostic implications for patients in the study.

      This clinical evaluation is intended to provide confirmatory evidence of the effectiveness
      and safety of the device Algisyl in patients with advanced heart failure.

Study Type


Primary Outcome

Peak VO2

Secondary Outcome

 NYHA Functional Class


Heart Failure



Study Arms / Comparison Groups

Description:  Algisyl device (implants) administered during a surgical procedure.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 2017

Completion Date

January 2024

Primary Completion Date

January 2020

Eligibility Criteria

        Inclusion Criteria:

          1. The patients must be able and willing to give written informed consent

          2. The patients will be adult (age ≥ 18 years and ≤ 79 years) males or females

          3. The patients must be on stable, evidence-based therapy for heart failure

             Evidence-based therapy for heart failure is defined as an ACE-inhibitor (ACE-I),
             and/or angiotensin II receptor blockers (ARB) for patients at stable doses for 1 month
             prior to enrollment, if tolerated, and a beta blocker (carvedilol, metoprolol
             succinate, Nebivolol or bisoprolol) for 3 months prior to enrollment, if tolerated.
             Recent up-titration of the beta blocker is acceptable if the patient has been stable
             on this dose for 1 month prior to enrollment. Stable is defined as no more than a 100%
             increase or a 50% decrease in dose. Contraindications or intolerance to therapies
             should be documented. In those intolerant to both ACE-I and ARB, combination therapy
             with hydralazine and oral nitrate should be considered. Therapeutic equivalence for
             ACE-I substitutions is allowed within the enrollment stability timelines. Aldosterone
             inhibitor therapy should be added when NYHA Class III or IV symptoms occur on standard
             therapy. If aldosterone inhibitor therapy is to be administered in NYHA Class II
             patients, it must be initiated and optimized prior to enrollment. Eplerenone requires
             dosage stability for 1 month prior to enrollment. Diuretics should be used as
             necessary to keep the patient euvolemic. All heart failure therapeutics and dosages
             should be documented in the Case Report Forms.

          4. The patient must have cardiac resynchronization therapy (CRT) if clinically indicated,
             implanted ≥3 months prior to randomization.

             * Note: In those patients not receiving CRT or CRT-D therapy the investigator should
             not anticipate initiating this therapy within 6 months after randomization

          5. The patient must have an implanted cardio-defibrillator (ICD) if clinically indicated,
             implanted at least 30 days prior to randomization.

             *Note: If the patient has clinical indications for an ICD but refuses the ICD, this
             refusal of ICD therapy must be document in the medical record and the patient may be
             enrolled with this documentation.

          6. The patients will have a left ventricular ejection fraction equal to or less than 35%
             via echocardiography, cardiac catheterization, radionuclide scan, or magnetic
             resonance imaging (measured within the last 30 days)

          7. The patients will have a left ventricular end diastolic dimension indexed to body
             surface area (LVEDDi) of greater than or equal to 30 mm/m2 (LVEDD/BSA) and an LVEDD of
             greater than or equal to 85 mm (measured within the last 30 days)

          8. Patients must have symptomatic heart failure with a Peak VO2 of 9.0 - 15.0 ml/min/kg
             (performed using a treadmill). Patients must perform two CPX tests (within 30 days of
             randomization and performed at least 20 hours apart) that differ by no more than 15%
             in the observed value for Peak VO2 and have a mean value of 9.0 - 15.0 ml/min/kg from
             these two tests. All CPX tests performed for the study must have a Peak Respiratory
             Exchange Ratio (RER) of at least 1.0 to be accepted as a valid test.

          9. Patient's surgical risk must be considered reasonable and the evaluation of surgical
             risk should include review of coronary and left ventricular angiography. Surgical risk
             assessment should include the consideration of risk presented by prior surgical
             procedures such as prior mid-sternotomy surgical procedures.

             *Note: investigators should observe standard clinical practice for the management of
             antithrombotic therapy in patients undergoing surgical procedures in accordance with
             the American College of Chest Physicians Guidelines: Perioperative management of
             antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th

         10. If female, the patients must be (a) post-menopausal, (b) surgically sterile, or (c)
             using adequate birth control and have a negative serum pregnancy test within 7 days
             prior to administration of study device

        Exclusion Criteria:

          1. Patients for whom it is planned to receive CABG, MVR, heart transplantation or LVAD
             within the next 6 months.

          2. Patients presenting with cardiogenic shock.

          3. Patients presenting with a restrictive cardiomyopathy such as due to amyloidosis,
             sarcoidosis, or hemochromatosis

          4. Patient with a history of constrictive pericarditis

          5. Patients with a Q wave myocardial infarction (MI) within the last 30 days

          6. Patients with a recent history of stroke (within 60 days prior to the surgical

          7. A left ventricular (LV) wall thickness of the LV free-wall, at the mid-ventricular
             level, of less than 8 mm (screening echocardiography must confirm a minimum wall
             thickness of 8 mm)

          8. Patients with an estimated glomerular filtration rate (GFR) < 30 mL/min/1.73 m2

          9. Clinically significant liver enzyme abnormalities, i.e., AST(SGOT) and ALT (SGPT) more
             than 2.5 times the upper limit of normal

         10. History of severe COPD (i.e., FEV 1< 1 liter or FEV1 < 50% predicted)

         11. The patients will not be receiving concurrently an Investigational Product in another
             clinical trial or have received an investigational Product in another clinical trial
             in the 30 days prior to enrollment

         12. A life expectancy of less than 1 year or any other condition that, in the opinion of
             the clinical investigator, might compromise any aspect of the trial




18 Years - 79 Years

Accepts Healthy Volunteers



, 949-679-6185, [email protected]

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

LoneStar Heart, Inc.

Study Sponsor

, , 

Verification Date

March 2017